

# Pierre-yves Salaun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4262633/publications.pdf>

Version: 2024-02-01

144  
papers

3,315  
citations

168829

31  
h-index

198040

52  
g-index

176  
all docs

176  
docs citations

176  
times ranked

3671  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients: A Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1070-1074.	2.8	8
2	Comparison of Volumetric Quantitative PET Parameters Before and After a CT-Based Elastic Deformation on Dual-Time 18FDG-PET/CT Images: A Feasibility Study in a Perspective of Radiotherapy Planning in Head and Neck Cancer. <i>Frontiers in Medicine</i> , 2022, 9, 831457.	1.2	0
3	Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. <i>Pharmaceuticals</i> , 2022, 15, 518.	1.7	8
4	Long-term recurrence risk after a first venous thromboembolism in men and women under 50 years old: A French prospective cohort. <i>European Journal of Internal Medicine</i> , 2021, 84, 24-31.	1.0	10
5	68Ga-Labelled Carbon Nanoparticles for Ventilation PET/CT Imaging: Physical Properties Study and Comparison with TechnegasA®. <i>Molecular Imaging and Biology</i> , 2021, 23, 62-69.	1.3	10
6	The Impact of Pulmonary Vascular Obstruction on the Risk of Recurrence of Pulmonary Embolism: A French Prospective Cohort. <i>Thrombosis and Haemostasis</i> , 2021, 121, 955-963.	1.8	5
7	Assessment of Image Quality and Lesion Detectability With Digital PET/CT System. <i>Frontiers in Medicine</i> , 2021, 8, 629096.	1.2	10
8	Clinical perspectives for the use of total body PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1712-1718.	3.3	12
9	Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors. <i>Scientific Reports</i> , 2021, 11, 4727.	1.6	3
10	Whole-body MR imaging in suspected physical child abuse: comparison with skeletal survey and bone scintigraphy findings from the PEDIMA prospective multicentre study. <i>European Radiology</i> , 2021, 31, 8069-8080.	2.3	8
11	Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism. <i>Circulation</i> , 2021, 143, 1828-1830.	1.6	18
12	Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 59.	3.8	52
13	Impressive Rapid Complete Response on FDG PET/CT to BRAF Inhibitors in a Metastatic Melanoma With Massive Tumor Burden. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, .	0.7	0
14	Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2021, 46, 111-118.	0.7	14
15	Fully Automated 68Ga-Labeling and Purification of Macroaggregated Albumin Particles for Lung Perfusion PET Imaging. <i>Frontiers in Nuclear Medicine</i> , 2021, 1, .	0.7	4
16	Good clinical practice recommendations for the use of PET/CT in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 28-50.	3.3	85
17	Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome. <i>Clinical Nuclear Medicine</i> , 2020, 45, 118-122.	0.7	14
18	Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Thrombosis Research</i> , 2020, 194, 153-157.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2622-2628.	1.9	10
20	Lung scintigraphy for pulmonary embolism diagnosis during the COVID-19 pandemic: does the benefit-risk ratio really justify omitting the ventilation study?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2499-2500.	3.3	14
21	The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 565086.	1.3	20
22	Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2910-2920.	1.9	11
23	Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinatate process from pancreatic neuroendocrine tumor. <i>Medicine (United States)</i> , 2020, 99, e20021.	0.4	6
24	V/Q SPECT for the Assessment of Regional Lung Function: Generation of Normal Mean and Standard Deviation 3-D Maps. <i>Frontiers in Medicine</i> , 2020, 7, 143.	1.2	7
25	Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study. <i>Thrombosis Research</i> , 2020, 194, 1-7.	0.8	13
26	Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. <i>Frontiers in Medicine</i> , 2020, 7, 218.	1.2	3
27	Integration of 18-FDG PET/CT in the Initial Work-Up to Stage Head and Neck Cancer: Prognostic Significance and Impact on Therapeutic Decision Making. <i>Frontiers in Medicine</i> , 2020, 7, 273.	1.2	6
28	Radiotherapy target volume definition in newly diagnosed high grade glioma using 18F-FET PET imaging and multiparametric perfusion MRI: A prospective study (IMAGG). <i>Radiotherapy and Oncology</i> , 2020, 150, 164-171.	0.3	11
29	Interobserver agreement of 18F-Fluorodeoxyglucose Positron-Emission Tomography combined with low-dose Computed Tomography for occult cancer screening in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2020, 188, 25-27.	0.8	2
30	Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone. <i>Frontiers in Medicine</i> , 2020, 6, 342.	1.2	5
31	Pulmonary perfusion by iodine subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary perfusion SPECT (PASEP trial). <i>European Radiology</i> , 2020, 30, 4857-4864.	2.3	8
32	Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. <i>Frontiers in Medicine</i> , 2020, 7, 599901.	1.2	0
33	Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma. <i>Medicine (United States)</i> , 2020, 99, e20021.	0.4	14
34	Prognostic value of textural indices extracted from pretherapeutic 18F-FDG PET/CT in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 495-502.	0.9	36
35	Computed tomography pulmonary angiography versus ventilation-perfusion lung scanning for diagnosing pulmonary embolism during pregnancy: a systematic review and meta-analysis. <i>Haematologica</i> , 2019, 104, 176-188.	1.7	56
36	Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice The PADIS-PE Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1489-1497.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Recommandations et recommandations. <i>Medecine Nucleaire</i> , 2019, 43, 1-4.	0.2	0
38	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1596-1604.	3.3	15
39	Diagnostic Value of FDG PET-CT Quantitative Parameters and Deauville-Like 5 Point-Scale in Predicting Malignancy of Focal Thyroid Incidentaloma. <i>Frontiers in Medicine</i> , 2019, 6, 24.	1.2	11
40	Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET/CT in head and neck cancer. <i>PLoS ONE</i> , 2019, 14, e0214299.	1.1	23
41	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. <i>Thrombosis Research</i> , 2019, 176, 79-84.	0.8	8
42	Time trend analysis of pulmonary embolism diagnosis with single-photon emission computed tomography ventilation/perfusion imaging. <i>Nuclear Medicine Communications</i> , 2019, 40, 576-582.	0.5	2
43	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	0.4	28
44	Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 578-579.	0.7	2
45	Comparison of 18F-Choline PET/CT and MRI functional parameters in prostate cancer. <i>Annals of Nuclear Medicine</i> , 2019, 33, 47-54.	1.2	0
46	Comparison of choline influx from dynamic 18F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment. <i>Annals of Nuclear Medicine</i> , 2018, 32, 281-287.	1.2	9
47	SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. <i>BMJ Open</i> , 2018, 8, e022024.	0.8	10
48	Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. <i>European Respiratory Journal</i> , 2018, 51, 1701202.	3.1	42
49	Imaging and identification of brown adipose tissue on CT scan. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 186-191.	0.5	7
50	Diagnostic performance of <sup>18</sup> F-fluorodesoxyglucose positron emission/computed tomography and magnetic resonance imaging in detecting T1&T2 head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2018, 128, 378-385.	1.1	13
51	New developments and future challenges of nuclear medicine and molecular imaging for pulmonary embolism. <i>Thrombosis Research</i> , 2018, 163, 236-241.	0.8	34
52	Target definition in salvage postoperative radiotherapy for prostate cancer: 18F-fluorocholine PET/CT assessment of local recurrence. <i>Acta Oncologica</i> , 2018, 57, 375-381.	0.8	9
53	An aortic intra mural hematoma in ventilation/perfusion SPECT/CT. <i>Medicine (United States)</i> , 2018, 97, e12928.	0.4	0
54	Clinical interest of quantitative bone SPECT-CT in the preoperative assessment of knee osteoarthritis. <i>Medicine (United States)</i> , 2018, 97, e11943.	0.4	22

#	ARTICLE	IF	CITATIONS
55	Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, e310-e311.	0.7	1
56	Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment. <i>EJNMMI Research</i> , 2018, 8, 49.	1.1	3
57	Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. <i>BMJ Open</i> , 2018, 8, e023939.	0.8	4
58	In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. <i>Thrombosis Research</i> , 2018, 171, 97-102.	0.8	6
59	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018, 171, 92-96.	0.8	20
60	Intérêt complémentaire de la TEP/TDM au FDG et de l'imagerie conventionnelle dans le bilan initial et le suivi post-thérapeutique des cancers des VADS: recommandations et perspectives. <i>Medecine Nucleaire</i> , 2018, 42, 422-427.	0.2	0
61	Feasibility of Systematic Respiratory-Gated Acquisition in Unselected Patients Referred for 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. <i>Frontiers in Medicine</i> , 2018, 5, 36.	1.2	8
62	A new SPECT/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases. <i>EJNMMI Research</i> , 2018, 8, 14.	1.1	21
63	Review article: FDG-PET in inflammatory diseases. <i>Medecine Nucleaire</i> , 2017, 41, 3-14.	0.2	1
64	Optimization of 18 F-Choline PET/CT acquisition in prostate cancer: Preliminary results concerning the length of the acquisition. <i>Medecine Nucleaire</i> , 2017, 41, 15-20.	0.2	0
65	Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2017, 155, 6-9.	0.8	11
66	Scintigraphie pulmonaire pour suspicion d'embolie pulmonaire aiguë: État des lieux des pratiques en France en 2014. <i>Medecine Nucleaire</i> , 2017, 41, 55-63.	0.2	0
67	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. <i>BMJ Open</i> , 2017, 7, e015562.	0.8	14
68	Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 1155-1165.	0.9	16
69	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	2.2	33
70	Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2017, 159, 48-51.	0.8	15
71	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2017, 167, 410.	2.0	96
72	Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2184-2187.	1.9	22

#	ARTICLE	IF	CITATIONS
73	Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. <i>Cancer Imaging</i> , 2017, 17, 16.	1.2	24
74	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , 2017, 4, 17.	1.3	14
75	Malignancy rate of focal thyroid incidentaloma detected by FDG PET-CT: results of a prospective cohort study. <i>Endocrine Connections</i> , 2017, 6, 413-421.	0.8	12
76	Isolated Cardiac Richter Syndrome: a Case Report. <i>Annals of Hematology</i> , 2017, 96, 147-149.	0.8	1
77	Clinical Validation of a Pixon-Based Reconstruction Method Allowing a Twofold Reduction in Planar Images Time of <sup>111</sup> In-Pentetreotide Somatostatin Receptor Scintigraphy. <i>Frontiers in Medicine</i> , 2017, 4, 143.	1.2	2
78	Performance of <sup>18</sup> F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2017, 12, e0178849.	1.1	3
79	Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. <i>Thrombosis and Haemostasis</i> , 2016, 116, 967-974.	1.8	96
80	Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase <sup>18</sup> F-FDG PET-CT imaging in patients with head and neck cancer. <i>Head and Neck</i> , 2016, 38, E600-6.	0.9	35
81	Pathologies prothrombotiques de hanche: intérêt de la médecine nucléaire. <i>Medecine Nucleaire</i> , 2016, 40, 404-410.	0.2	2
82	An atypical sarcoidosis involvement in FDG PET/CT. <i>Medicine (United States)</i> , 2016, 95, e5700.	0.4	5
83	Does PET SUV Harmonization Affect PERCIST Response Classification?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1699-1706.	2.8	31
84	Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide. <i>International Journal of Hematology</i> , 2016, 104, 400-402.	0.7	1
85	Value of <sup>18</sup> F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 773-779.	3.3	56
86	Limited screening with versus without <sup>18</sup> F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. <i>Lancet Oncology</i> , 2016, 17, 193-199.	5.1	83
87	Additional value of combining low-dose computed tomography to V/Q SPECT on a hybrid SPECT-CT camera for pulmonary embolism diagnosis. <i>Nuclear Medicine Communications</i> , 2015, 36, 922-930.	0.5	34
88	Asymmetric Muscle Activity on <sup>18</sup> F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e336-e337.	0.7	2
89	Interest of chest X-ray in tailoring the diagnostic strategy in patients with suspected pulmonary embolism. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 643-648.	0.5	1
90	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. <i>Frontiers in Medicine</i> , 2015, 2, 84.	1.2	29

#	ARTICLE	IF	CITATIONS
91	Recherche de contamination atmosphérique dans un service de médecine nucléaire. <i>Medecine Nucleaire</i> , 2015, 39, 192-198.	0.2	2
92	Value of ventilation/perfusion SPECT for diagnosis of pulmonary embolism: response to comments by Sinzinger et al.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 979-980.	3.3	0
93	Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 72-78.	3.3	29
94	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1212-1217.	2.8	36
95	Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 31.	3.8	195
96	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2072-2082.	3.3	81
97	Performance of 18F fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for the diagnosis of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 135, 31-35.	0.8	18
98	Role of SPECT/CT Compared With MRI in the Diagnosis and Management of Patients With Wrist Trauma Occult Fractures. <i>Clinical Nuclear Medicine</i> , 2014, 39, 8-13.	0.7	28
99	Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 659-667.	3.3	59
100	Safety of ventilation/perfusion single photon emission computed tomography for pulmonary embolism diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1957-1964.	3.3	34
101	18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	3.3	14
102	Interpretation of suspect head and neck fixations seen on PET/CT in lung cancer. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2014, 131, 217-221.	0.4	8
103	Prediction of HNSCC recurrence by using kinetic and volumetric FDG-PET parameters.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6081-6081.	0.8	0
104	Two Years Versus Six Months of Oral Anticoagulation after a First Episode of Unprovoked Pulmonary Embolism: The Padis PE Multicenter, Double-Blind, Randomized Trial. <i>Blood</i> , 2014, 124, LBA-3-LBA-3.	0.6	3
105	Early recurrence or submucosal residual of laryngeal squamous cell carcinoma: Diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach. <i>Head and Neck</i> , 2013, 35, E202-4.	0.9	1
106	Initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding) locations outside of the upper aerodigestive tract. 2012 SFORL guidelines. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2013, 130, 107-112.	0.4	37
107	Initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding) Otorhinolaryngology, Head and Neck Diseases, 2013, 130, 39-45.	0.4	42
108	V/Q SPECT Interpretation for Pulmonary Embolism Diagnosis: Which Criteria to Use?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1077-1081.	2.8	41

#	ARTICLE	IF	CITATIONS
109	Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nuclear Medicine Communications, 2013, 34, 551-556.	0.5	27
110	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. Journal of Nuclear Medicine, 2012, 53, 1185-1192.	2.8	74
111	Diagnosis of pulmonary embolism. Nuclear Medicine Communications, 2012, 33, 695-700.	0.5	7
112	Diagnostic Accuracy of Single-Photon Emission Tomography Ventilation/Perfusion Lung Scan in the Diagnosis of Pulmonary Embolism. Chest, 2012, 141, 381-387.	0.4	55
113	Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1839-1847.	3.3	32
114	External validation of a D-dimer age-adjusted cut-off for the exclusion of pulmonary embolism. Thrombosis and Haemostasis, 2012, 107, 1005-1007.	1.8	22
115	Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with head and neck squamous cell carcinoma. Head and Neck, 2012, 34, 462-468.	0.9	25
116	Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). Tumor Biology, 2012, 33, 601-606.	0.8	14
117	Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. Medecine Nucleaire, 2011, 35, 600-607.	0.2	5
118	Radiothérapie vectorisée: les nouvelles molécules. Medecine Nucleaire, 2011, 35, 613-616.	0.2	1
119	American consensus recommendations for gastric scintigraphy. Nuclear Medicine Communications, 2011, 32, 30-36.	0.5	2
120	Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1064-1071.	3.3	87
121	Noninvasive Diagnosis of Pulmonary Embolism. Chest, 2011, 139, 1294-1298.	0.4	59
122	MRI in Acute Pulmonary Embolism: Response. Chest, 2011, 140, 1391-1392.	0.4	1
123	Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma. Nuclear Medicine Communications, 2010, 31, 766-772.	0.5	27
124	Detection of occult wrist fractures. Nuclear Medicine Communications, 2010, 31, 178-179.	0.5	1
125	Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer, 2010, 116, 1053-1058.	2.0	25
126	Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer, 2010, 116, 1118-1125.	2.0	19



#	ARTICLE	IF	CITATIONS
127	Comments Regarding "Consensus Recommendations for Gastric Emptying Scintigraphy". American Journal of Gastroenterology, 2010, 105, 2705.	0.2	0
128	Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3889-3889.	0.6	1
129	La place de l'ATP au FDG dans l'évaluation des lymphomes. Hematologie, 2009, 15, 305-312.	0.0	0
130	Does <sup>18</sup> F-FDG PET/CT Improve the Detection of Posttreatment Recurrence of Head and Neck Squamous Cell Carcinoma in Patients Negative for Disease on Clinical Follow-up?. Journal of Nuclear Medicine, 2009, 50, 24-29.	2.8	231
131	Analysis of <sup>18</sup> F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1813-1821.	3.3	111
132	Intérêt de la tomographie par émission de positons (TEP) au <sup>18</sup> F-FDG dans le suivi des patients traités pour carcinome épidermoïde des voies aérodigestives supérieures (VADS) en pratique clinique. Medecine Nucleaire, 2009, 33, 193-200.	0.2	0
133	Validité de la somme angulaire comme technique d'extraction d'images planaires à partir de données tomoscintigraphiques pulmonaires de ventilation-perfusion. Medecine Nucleaire, 2009, 33, 533-538.	0.2	1
134	Detection of occult wrist fractures by quantitative radiosintigraphy: a prospective study on selected patients. Nuclear Medicine Communications, 2009, 30, 862-867.	0.5	19
135	La radio-immunothérapie en clinique. Medecine Nucleaire, 2008, 32, 254-257.	0.2	1
136	Management of suspected pulmonary embolism patients with low clinical and low V/Q probability. Thrombosis Research, 2008, 122, 450-454.	0.8	2
137	FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica, 2008, 93, 1269-1271.	1.7	70
138	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4590-4597.	1.8	89
139	Does <sup>18</sup> F-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up?. Head and Neck, 2007, 29, 1115-1120.	0.9	51
140	Comparison of gastric emptying scintigraphy based on the geometric mean of the gastric proportion of the abdominal radioactivity or on the geometric mean of the intragastric radioactivity. Nuclear Medicine Communications, 2006, 27, 431-437.	0.5	8
141	Optimized radioiodine therapy for Graves' disease: Two MIRD-based models for the computation of patient-specific therapeutic <sup>131</sup> I activity. Nuclear Medicine Communications, 2006, 27, 559-566.	0.5	16
142	<sup>99m</sup> Tc ovalbumin labelled eggs for gastric emptying scintigraphy: in-vitro comparison of solid food markers. Nuclear Medicine Communications, 2005, 26, 1021-1025.	0.5	2
143	Management of suspected venous thromboembolism: the impact of a multifaceted intervention. International Journal for Quality in Health Care, 2005, 17, 433-438.	0.9	2
144	An analysis of the <sup>18</sup> F-FDG uptake pattern in the stomach. Journal of Nuclear Medicine, 2005, 46, 48-51.	2.8	32